Allurion announces plans to combine glp-1 therapy with the allurion balloon to treat obesity

Natick, mass.--(business wire)---- $alur--allurion technologies, inc. (“allurion” or the “company”) (nyse: alur), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the allurion balloon with glp-1 agonists. the study will focus on combination use of the allurion balloon with lower dose glp-1s with the goal of demonstrating improved long-term tolerability and adherence to glp-1 therapy. previous studies have shown that 30% of patients di.
ALUR Ratings Summary
ALUR Quant Ranking